Innovative graphene biosensor assays on track for 2027 release to facilitate home-based infectious disease testing

GRIP Medical Diagnostics biosensor technology has the potential to alter how diseases are detected, diagnosed, monitored, and treated (video)

A successful clinical feasibility study was announced today that may reshape the landscape of DIY at-home medical diagnostic testing.

Visit the GRIP Molecular table in Exhibit Hall A- 801, Innovation Pavilion and discover how we are making a difference in the world of at home medical testing.

The relationship between IoT, biotechnology & medical devices has the potential to revolutionize the healthcare industry and improve patient outcomes for generations to come.

GRIP Molecular is working with BARDA on a single-use, hand-held cartridge that is designed to enable lab-grade accuracy, multiplexed detection of SARS-CoV-2, influenza A and B, RSV, and other common pathogens using a nasal swab sample. Their proprietary biosensor technology is intended to provide results within five minutes and read-out on a standard mobile device.

GRIP attended BARDA Innovation Showcase bringing together top health security companies, government and private sector ecosystem partners, investors, and strategic partners.

GRIP will showcase their DIY at home medical diagnostics technology that deliver lab grade results w/o the need for centralized laboratories.

Video Presentation by Dr. Bruce Batten PhD and Chief Scientific Officer of GRIP Molecular in Washington DC to Bi Partisan Commission on Bio Defense

GRIP will share work that benefitted from collaborating with
Biological Advanced Research Development Authority @BARDA and Johnson & Johnson Innovation @JLABS

A personal video message from CEO to GRIP friends and family about the company mission for the rapid advancement of an at home infectious disease (ID) testing technology being developed by GRIP Molecular and the University of MN.

GRIP Molecular introduces novel DIY at-home lab testing technology powered by smartphones.

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by a smartphone. The innovation opens the door for faster and more affordable at-home medical testing.

The startup is kicking off clinical validation studies for a single-use, at-home testing platform that uses up to 32 graphene biosensors within a poker chip-sized fluidic cartridge.

A joint initiative was announced between GRIP Molecular, Johnson and Johnson Innovation (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA) for the development of graphene-based electronic biosensor technology

Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.

On behalf of the entire GRIP Molecular team and investors, congratulations on this wonderful award. For those that do not know, with the extraordinary participation of over 400 of the leading medical technology companies, AdvaMed advocates globally for the highest ethical standards and patient access to safe, effective and innovative medical technologies that save and improve lives. We at GRIP are grateful to have experienced your personification of these ideals. We are very proud to have you as our Board Chair and today will bask in the glow of AdvaMed’s recognition of your lifetime of impactful accomplishment.

GRIP Molecular is mentioned in this trade journal write up of cutting edge Graphene Biosensor Companies

GRIP Molecular featured as one of top picks for the best Minnesota based Therapeutics companies and start-ups

The Regents of the University of Minnesota through the Discovery Capital matching seed program have made an investment in GRIP Molecular’s seed round.

GRIP Molecular was honored to receive both the “People’s Choice” and “Judge’s Choice” awards during the MedCity News – INVEST Pitch Perfect contest.

In Minnesota, one of the nation’s top three medtech hubs, the state Department of Employment and Economic Development (DEED) has distributed $1.6 million per year since 2019 in innovation grants to tech startups

GRIP Molecular has successfully raised funds to complete proof-of-concept experiments, gain exclusive rights to the underlying IP, activate its research facility, sponsor research activities at

The Tech Tribune staff has compiled the very best tech startups in St. Paul, Minnesota. In doing our research, we considered several factors including but not limited to:

1. Revenue potential
2. Leadership team
3. Brand/product traction
4. Competitive landscape

Additionally, all companies must be independent (unacquired), privately owned, at most 10 years old, and have received at least one round of funding in order to qualify.

Seven University of Minnesota startup companies were today awarded Launch Minnesota Innovation Grants by the Minnesota Department of Employment and Economic Developments (DEED). DEED staff targets these new grants, 20 of which were announced today, at “the most promising, innovative, and scalable technology businesses in the state” based on the recommendations of an advisory board to Launch Minnesota, a statewide collaborative effort to accelerate the growth of startups and amplify Minnesota as a national leader in innovation.